Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Appendix B: Drug Characteristics Tables
Characteristics of the CCR5 Antagonist
Last Updated: December 18, 2019; Last Reviewed: December 18, 2019
||14–18 hours||CYP3A4 substrate||
Upper respiratory tract infections
Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions
Orthostatic hypotension, especially in patients with severe renal insufficiency
a For dose adjustment in patients with hepatic insufficiency, see Appendix B, Table 10.
b Also see Table 17.
Key: CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PO = orally; RAL = raltegravir; T-20 = enfuvirtide; TPV/r = tipranavir/ritonavir